Rubitecan: 9-NC, 9-Nitro-20(S)-Camptothecin, 9-Nitro-Camptothecin, 9-Nitrocamptothecin, RFS 2000, RFS2000

Drugs in R and D

Volumn 5, Issue 5, 2004, Pages 305-311

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAMPTOTHECIN DERIVATIVE; CAPECITABINE; DNA TOPOISOMERASE INHIBITOR; GEMCITABINE; LACTONE DERIVATIVE; LIPOSOME; ORPHAN DRUG; RADIOSENSITIZING AGENT; RUBITECAN;

ABDOMINAL PAIN; ADVANCED CANCER; ALOPECIA; ANEMIA; ANGIOPLASTY; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; ASTHENIA; BARK; BLOOD TOXICITY; BODY WEIGHT DISORDER; BONE CANCER; BREAST CANCER; CAMPTOTHECA; CANADA; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOVASCULAR PROCEDURES; CATHETER ABLATION; CELL PROLIFERATION; CHEMICAL CYSTITIS; CHEMICAL MODIFICATION; CHINA; CHORDOMA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COMMERCIAL PHENOMENA; CONSTIPATION; DATA ANALYSIS; DEHYDRATION; DENMARK; DIARRHEA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG ISOLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DYSPNEA; EPISTAXIS; EUROPEAN UNION; FATIGUE; FEVER; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; FRANCE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GERMANY; HEAD AND NECK CANCER; HEALTH PROGRAM; HEART MUSCLE ISCHEMIA; HEMATOLOGIC MALIGNANCY; HEMATURIA; HOME CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HYPERBILIRUBINEMIA; INFECTION; ISCHEMIC HEART DISEASE; ITALY; JAPAN; LUNG CANCER; LUNG METASTASIS; MEDICAL SPECIALIST; METASTASIS; MEXICO; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NETHERLANDS; NEUTROPENIA; NONHUMAN; ONCOLOGY; OUTPATIENT CARE; OVARY CANCER; PAIN; PANCREAS CANCER; PATENT; PLANT LEAF; PRELEUKEMIA; PRIORITY JOURNAL; PROSTATE CANCER; SAMPLE SIZE; SEPSIS; SOLID TUMOR; SPAIN; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TREATMENT FAILURE; UNITED KINGDOM; UNITED STATES; UTERINE CERVIX CANCER; VOMITING; WEIGHT REDUCTION;

ANIMALS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIVIRAL AGENTS; CAMPTOTHECA; CAMPTOTHECIN; CLINICAL TRIALS, PHASE I AS TOPIC; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 7244245654     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200405050-00007     Document Type: Article

References (21)

1. SuperGen Inc. SuperGen Submits Application for EMEA Approval of Orathecin™. Media Release: 1 Jul 2004. Available from URL: http://www.supergen.com
2. SuperGen Inc. SuperGen's Orathecin (rubitecan) capsules granted 'orphan product' status in Europe. Media Release: 11 Jun 2003. Available from URL: http://www.supergen.com
3. SuperGen Inc. SuperGen Reports Results of Phase III Study of Orathecin™ In Patients With Advanced Pancreatic Cancer. Media Release: 30 May 2003. Available from: URL: http://www.supergen.com
4. SuperGen Inc. SuperGen Announces Additional Data from (Phase III Study of Orathecin™ in Patients With Advanced Pancreatic Cancer. Media Release: 2 Jun 2003. Available from URL: http:/ /www.supergen.com
5. SuperGen Inc. SuperGen Receives Patent Notices of Allowance for Rubitecan-Related Claims. Media Release: 16 Jul 2003. Available from URL: http://www.supergen.com
6. Verschraegen CF, Natelson EA, Giovanella BC, et al. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anti-Cancer Drugs 9: 36-44, Jan 1998
7. Verschraegen CF, Harris N, Steger M. Pharmacology study of multiple oral doses of 9-nitro-camptothecin. Annals of Oncology 9 (Suppl. 2): 70, 1998
8. Verschraegen CF, Gupta E, Loyer E. A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anti-Cancer Drugs 10: 375-383, Apr 1999
9. Schöffski P, Herr A, Beijnen J, et al. Effect of food intake on the pharmacokinetics of a single administration of oral Rubitecan (RFS-2000), a topoisomerase-I-inhibiting camptothecin analogue. 11th NCI-EORTC-AACR symposium on new drugs in cancer therapy: 91 (plus poster), 7 Nov 2000
10. Schöffski P, Herr A, van den Brande J, et al. Effect of food intake on the pharmacokinetics of the oral camptothecin analogue rubitecan: phase II- and pharmacologic evaluation in non-pretreated patients with metastatic colorectal cancer. Onkologie 24 (Suppl. 6): 4, Sep 2001
11. SuperGen. SuperGen's RFS 2000 shows 63% response or stable disease in pancreatic cancer patients. Longest survival data - 16.2 months - ever reported for pancreatic cancer patients. Media Release [2 pages], 27 May 1998
12. SuperGen Inc. M.D. Anderson study concludes SuperGen's rubitecan is active in chronic myelomonocytic leukemia (CM-ML) and myelodysplastic syndromes (MDS). Media Release [2 pages], 11 Dec 2001. Available from URL: http://www.supergen.com
13. Konstadoulakis MM, Antonakis PT, Tsibloulis BG, et al. A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology 48: 417-420, Nov 2001
14. Ellerhorst JA, Bedikian AY, Smith TM, et al. Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma. Anti-Cancer Drugs 13: 169-172, Feb 2002
15. Michaelson MD, Ryan DP, Fuchs CS, et al. A phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors. Cancer 97: 148-154, 1 Jan 2003
16. Pantazis P, Mendoza JT, Early JA, et al. 9-Nitro-camptothecin delays growth of U-937 leukemia tumors in nude mice and is cytotoxic or cytostatic for human myelomonocytic leukemia lines in vitro. European Journal of Haematology 50: 81-89, Feb 1993
17. Pantazis P, Early JA, Kozielski AJ, et al. Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Research 53: 1577-1582, 1 Apr 1993
18. Moulton S, Pantazis P, Epstein JS, et al. 9-Nitrocamptothecin inhibits tumor necrosis factor-mediated activation of human immunodeficiency virus type 1 and enhances apoptosis in a latently infected T cell clone. AIDS Research and Human Retroviruses 14: 39-49, 1 Jan 1998
19. Hung C-L, Doniger J, Palini A, et al. 9-Nitrocamptothecin inhibits HIV-1 replications in human peripheral blood lymphocytes: a potential alternative for HIV-infection/AIDS therapy. Journal of Medical Virology 64: 238-244, No. 3, 2001
20. SuperGen Inc. Study shows SuperGen's rubitecan has significant activity in several hematological malignancies. Media Release [2 pages], 15 Sep 2000. Available from URL: http://www.supergen.com
21. SuperGen Inc. Independent Review of Orathecin™ Phase III Trial Supports Drug's Activity in Pancreatic Cancer Patients who Failed Prior Treatments. Media Release: 17 Nov 2003. Available from URL: http://www.supergen.com